Innate Pharma Reports Full Year 2024 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the year ending December 31, 2024. The consolidated financial statements are attached to this press release. “Our strategy is clear: drive innovation through our ANKET® NK-cell engager platform and accelerate our ADC programs. We are making strong clinical progress, with our lead proprietary ANKET®, IPH6501 ad